Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...

Boehringer Ingelheim’s FIBRONEER-ILD phase III study of nerandomilast to treat progressive pulmonary fibrosis meets primary endpoint: Ingelheim, Germany Wednesday, February 12, ...

The "Cough in Idiopathic Pulmonary Fibrosis (IPF) - Epidemiology Forecast - 2034" report has been added tAndMarkets.com's offering.The report delivers an in-depth understanding of the Cough in ...

Prospective study on abemaciclib-induced interstitial lung disease in metastatic breast cancer reveals a 7.4% incidence rate.

Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...

Topline data from FIBRONEER-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in forced vital capacity [mL] at week 52 vers ...

C, BSN, RN, illustrated the importance of consistent care to identify AEs like interstitial lung disease in patients with cancer.

The following is a summary of “Diagnosis, screening, and follow-up of patients with familial interstitial lung disease: ...

Zenocutuzumab helps fill an important need for patients with advanced pancreatic cancer and NSCLC with NRG1 gene fusions, said Alison Schram M.D., ...

Pneumonia is a lung infection caused by bacteria, viruses, fungi, or tuberculosis. Symptoms include fever, cough, chest pain, and shortness of breath.

Asbestos can cause serious illnesses that develop 20-50 years after the inhalation or ingestion of asbestos fibers. These fibers can also result in fluid and plaque buildup over time. Many companies ...